Indiana § 12-23-18-7.5 Office based opioid treatment providers; treatment protocol; clinical
practice guidelines

Indiana Statutes

§ 12-23-18-7.5 — Office based opioid treatment providers; treatment protocol; clinical practice guidelines

Indiana § 12-23-18-7.5

Art. 23ADDICTION SERVICES

Ch. 18Opioid Treatment Diversion Control and Oversight

This text of Indiana § 12-23-18-7.5 (Office based opioid treatment providers; treatment protocol; clinical practice guidelines) is published on Counsel Stack Legal Research, covering Indiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Ind. Code § 12-23-18-7.5 (2026).

Text

5.

(a)This section applies to an office based opioid treatment provider who:

(1)has obtained a waiver from the federal Substance Abuse and Mental Health Services Administration (SAMHSA) and meets the qualifying standards required to treat opioid addicted patients in an office based setting; and

(2)has a valid federal Drug Enforcement Administration registration number and identification number that specifically authorizes treatment in an office based setting.

(b)The office of the secretary and the division shall develop a treatment protocol containing best practice guidelines for the treatment of opiate dependent patients. The treatment protocol must require the minimal clinically necessary medication dose, including, when appropriate, the goal of opioid abstinence, and including the f

Free access — add to your briefcase to read the full text and ask questions with AI

5. (a) This section applies to an office based
opioid treatment provider who:
(1) has obtained a waiver from the federal Substance Abuse and
Mental Health Services Administration (SAMHSA) and meets the
qualifying standards required to treat opioid addicted patients in
an office based setting; and
(2) has a valid federal Drug Enforcement Administration
registration number and identification number that specifically
authorizes treatment in an office based setting.
(b) The office of the secretary and the division shall develop a
treatment protocol containing best practice guidelines for the treatment
of opiate dependent patients. The treatment protocol must require the
minimal clinically necessary medication dose, including, when
appropriate, the goal of opioid abstinence, and including the following:
(1) Appropriate clinical use of any drug approved by the federal
Food and Drug Administration for the treatment of opioid
addiction, including the following:
(A) Opioid maintenance.
(B) Opioid detoxification.
(C) Overdose reversal.
(D) Relapse prevention.
(E) Long acting, nonaddictive medication assisted treatment
medications.
(2) A requirement for initial and periodic behavioral health
assessments for each patient.
(3) Appropriate use of providing overdose reversal, relapse
prevention, counseling, and ancillary services.
(4) Transitioning off agonist and partial agonist therapies, when
appropriate, with the goal of opioid abstinence.
(5) Training and experience requirements for prescribers of drugs
described in subdivision (1) in the treatment and management of
opiate dependent patients.
(6) A requirement that prescribers obtain informed consent from
a patient concerning all available opioid treatment options,
including each option's potential benefits and risks, before
prescribing a drug described in subdivision (1).
(c) Before December 31, 2016, the office of the secretary shall
recommend the clinical practice guidelines required under subsection
(b) to:
(1) the Indiana professional licensing agency established under IC 25-1-5;
(2) the office of Medicaid policy and planning established under
IC 12-8-6.5; and
(3) a managed care organization that has contracted with the
office of Medicaid policy and planning.